Brii Biosciences Limited (BRII-B) executed an on-market buyback of 120,000 ordinary shares on 25 August 2026, paying between HKD 0.995 and HKD 1.03 per share for a total consideration of HKD 0.12 million. The volume-weighted average price was approximately HKD 1.01 per share.

Following the transaction, issued shares outstanding (excluding treasury stock) decreased by 0.02 % to 722.05 million, while treasury shares increased to 12.90 million. The company’s total issued share count remained unchanged at 734.96 million shares, as the repurchased stock has been retained as treasury shares rather than cancelled.

The repurchase forms part of the mandate approved on 16 June 2026, which authorises buybacks of up to 72.19 million shares. To date, Brii Bio has repurchased 0.18 million shares under this mandate, representing 0.02 % of shares outstanding at the time the authority was granted. In accordance with Hong Kong Stock Exchange regulations, the company is restricted from issuing new shares or disposing of treasury shares until 24 September 2026.